11 Oversold Healthcare Stocks To Buy Right Now

Published on March 13, 2024 at 8:17 am by Fatima Farooq in Hedge Funds, News

In this article, we will be taking a look at 11 oversold healthcare stocks to buy right now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Oversold Healthcare Stocks To Buy Right Now.

The Healthcare Sector: The New 2024 Idea?

The healthcare sector has been popular among investors for some time now, but it is starting to become the new “2024 idea” for investing portfolios because of its performance so far. Biotechnology companies, in particular, have been seen to have a “massive breakout” in February, according to BTIG’s Chief Market Technician, Jonathan Krinsky, who joined CNBC’s “Closing Bell” to discuss the potential upside for the healthcare sector this year on February 27. Here are some of his comments:

“It [healthcare] was our top pick in December, coming into the year. I think it started with the mega caps, Eli Lilly, that kind of trade. Now we’re seeing a broadening. If you look at year-to-date performance on an equal weight basis, healthcare is the best performing sector on an equal weight basis. So it is brought underneath, and you know, if you compare it to technology it’s not had the big hockey stick moves right now, so I think there’s still some runway to go.”

Considering Krinsky’s comments, it is unsurprising that many are now looking at the healthcare sector this year as a viable and potentially attractive investment opportunity. Though the sector may lack some of the excitement associated with the technology sector, and artificial intelligence stocks in particular, healthcare is now beginning to take the stage as an alluring investment space with immense room to grow in profitability and upside potential. This is especially the case if one is looking to invest in top performers in the healthcare sector, such as Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Company (NYSE:BMY), and AbbVie Inc. (NYSE:ABBV).

Obesity and Weight Loss Drugs: A Newly Popular Area in Healthcare

One of the most popular areas within the healthcare sector today is that of obesity and weight loss drugs. A major player in this area is the mega-cap Eli Lilly and Company (NYSE:LLY), mentioned by Krinsky on CNBC’s “Closing Bell.” This company has been working tirelessly in the past to highlight obesity as a medical condition that requires proper attention and diagnosis alongside treatment. Dr. Angela Fitch, a Chief Medical Officer at Knownwell and President of the Obesity Medicine Association, joined CNBC’s “Squawk Box” on March 8 to discuss Eli Lilly and Company’s (NYSE:LLY) new obesity drug ads. Here are some of her observations on the matter:

“Obesity as a chronic disease has not gotten the attention it deserves. It’s the biggest epidemic in our country and the world actually right now, and it’s just nice to see this sort of public service annoucement recognizing the criticality of treating obesity today as a chronic disease.”

According to Dr. Fitch, over a hundred million people in the US qualify for treatment when it comes to the disease of obesity, a figure that underscores the pertinence of this issue, particularly in the US, and highlights the existence of a massive market for obesity and weight loss drugs from the perspective of companies marketing these products. A contentious point up for debate when it comes to these drugs, though, is their highly expensive prices. Healthcare companies charge massive amounts for granting access to these drugs, which may serve them well by way of profitability and may be an attractive point from an investment point of view. Still, the US government has been attempting to regulate the prices of these drugs for the benefit of the regular consumer who may be in dire need of obesity medication but unable to afford it. Whatever the outcome of the pricing debate may be, it is undeniable that healthcare companies are beginning to attract attention this year. As a result, it may be a good idea to keep an eye on which names in this sector are oversold stocks or overbought stocks. We have thus compiled a list of oversold stocks in the healthcare sector. These include some cheap healthcare stocks and other healthcare stocks to consider investing in.

Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements.

Our Methodology

We used the Relative Strength Index (RSI) indicator to pick oversold stocks in the healthcare sector for our list. The RSI indicator is a momentum indicator used in the technical analysis of stocks by measuring the speed and magnitude of a security’s recent price changes to evaluate whether the price of that security is overvalued or undervalued. Stocks with RSI values of over 70 are traditionally considered overbought, while those with RSI values under 30 are oversold. We used a stock screener to find healthcare stocks with RSI values under 30 and then ranked them based on this metric, from the highest to the lowest RSI value. We also mentioned the number of hedge funds holding stakes in each stock, using Insider Monkey’s hedge fund data for the fourth quarter. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by over 140 percentage points over the last 10 years (see the details here). That’s why we pay very close attention to this often-ignored indicator.

Oversold Healthcare Stocks To Buy Right Now

11. 10x Genomics, Inc. (NASDAQ:TXG)

Number of Hedge Fund Holders: 30

14-day RSI as of March 12: 30

10x Genomics, Inc. (NASDAQ:TXG) is a life sciences tools and services company based in Pleasanton, California. The company develops and sells instruments, consumables, and software for analyzing biological systems across the globe.

On February 16, analysts at Stifel maintained a Buy rating and a $63 price target on 10x Genomics, Inc. (NASDAQ:TXG).

In the fourth quarter, 30 hedge funds were long 10x Genomics, Inc. (NASDAQ:TXG), with a total stake value of $572.1 million.

Baron Funds mentioned 10x Genomics, Inc. (NASDAQ:TXG) in its third-quarter 2023 investor letter:

“We initiated a position in 10x Genomics, Inc. (NASDAQ:TXG), a company that sells innovative instruments and reagents for life sciences research. The company’s first platform, the Chromium, is dominant within the single-cell space. The Chromium utilizes advanced microfluidics to separate a sample into individual cells. Each cell is enveloped in its own droplet, where an individual reaction occurs to detect the expression profile of that cell. This occurs in parallel across tens of thousands of droplets, enabling high-throughput and granular characterization of a sample. 10x Genomics’ second platform is the Visium platform for spatial analysis. Visium employs a slide with many small dots (55 microns in diameter), each of which has a unique barcode. The barcodes are read by next-generation sequencing equipment. This enables researchers to detect expression patterns (genetic behavior) across geographic regions of a tissue sample. Finally, the company is launching its third major platform, the Xenium for in-situ analysis. The in-situ platform allows researchers to visualize biomarkers of interest right on the tissue slide, in real time. The images are processed on-instrument versus Visium, which requires barcodes that a separate sequencer reads.

Our conviction in 10x Genomics is driven by multiple growth drivers over the next several years. First, for the single-cell platform, the company has a new kit called Flex that enables sample multiplexing and working with FFPE (preserved) samples. We think this opens up translational studies that rely on archival samples. This marks an opportunity to expand into biopharmaceuticals (whereas historically the company has been predominantly conducting basic research). Second, we think there is upside from the new product cycle with the in-situ Xenium. We believe the platform is differentiated by its throughput, paired with a panel approach that allows customers to add customization to their research projects. In the near term,10X Genomics’ margins may be pressured by the bolus of Xenium boxes being placed, which are generally, lower-margin razors. This will eventually lead to a stream of consumables (razor blades) sales at much higher margins. We like 10x Genomics as a high-quality life science research company with multiple shots on goal. The company has a strong balance sheet with $400 million in cash and no debt, and with visibility to FCF breakeven in the near term. We see 10x Genomics as a consistent double-digit grower, with over 80% of revenues coming from high-margin and recurring consumables, roughly 70% gross margins, and a path to over 30% EBITDA margins longer term.”

While being part of our oversold stocks list, 10x Genomics, Inc. (NASDAQ:TXG) may be an attractive healthcare stock to buy, like Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Company (NYSE:BMY), and AbbVie Inc. (NYSE:ABBV).

10. MaxCyte Inc. (LON:MXCT)

Number of Hedge Fund Holders: 14

14-day RSI as of March 12: 29.75

There were 14 hedge funds long MaxCyte Inc. (LON:MXCT) in the fourth quarter, with a total stake value of $68.9 million.

MaxCyte Inc. (LON:MXCT) is another life sciences tools and services company on our list of oversold stocks. The company is based in Rockville, Maryland. It discovers, develops, and commercializes next-generation cell therapies.

Cadian Capital was the largest shareholder in MaxCyte Inc. (LON:MXCT) at the end of the fourth quarter, holding 5.6 million shares in the company.

9. Seres Therapeutics, Inc. (NASDAQ:MCRB)

Number of Hedge Fund Holders: 20

14-day RSI as of March 12: 29.58

An Outperform rating and a $5 price target were maintained on Seres Therapeutics, Inc. (NASDAQ:MCRB) on March 6 by analysts at Oppenheimer.

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a biotechnology company on our list of oversold stocks. The company develops microbiome therapeutics to treat the modulation of the colonic microbiome.

In total, 20 hedge funds were long Seres Therapeutics, Inc. (NASDAQ:MCRB) in the fourth quarter, with a total stake value of $22.3 million.

8. Integra Lifesciences Holdings Corporation (NASDAQ:IART)

Number of Hedge Fund Holders: 29

14-day RSI as of March 12: 29.56

Holding 53.7 million shares in the company, Highbridge Capital Management was the largest shareholder in Integra Lifesciences Holdings Corporation (NASDAQ:IART) at the end of the fourth quarter.

Integra Lifesciences Holdings Corporation (NASDAQ:IART) is a healthcare equipment company on our list of oversold stocks. The company manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.

JMP Securities analysts maintained a Market Outperform rating and a $49 price target on Integra Lifesciences Holdings Corporation (NASDAQ:IART) on February 29.

We saw 29 hedge funds long Integra Lifesciences Holdings Corporation (NASDAQ:IART) in the fourth quarter, with a total stake value of $249.4 million.

7. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Number of Hedge Fund Holders: 31

14-day RSI as of March 12: 29.32

Axsome Therapeutics, Inc. (NASDAQ:AXSM) was spotted in the 13F holdings of 31 hedge funds in the fourth quarter, with a total stake value of $968.4 million.

As of March 4, HC Wainwright & Co. analysts maintain a Buy rating and a $180 price target on Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a pharmaceutical company based in New York on our list of oversold stocks. It develops novel therapies for central nervous system disorders in the US.

6. PetMed Express, Inc. (NASDAQ:PETS)

Number of Hedge Fund Holders: 15

14-day RSI as of March 12: 29.05

Driehaus Capital was the largest shareholder in PetMed Express, Inc. (NASDAQ:PETS) at the end of the fourth quarter, holding 732,155 shares in the company.

PetMed Express, Inc. (NASDAQ:PETS) operates as a pet pharmacy in the US and is based in Delray Beach, Florida. The company markets prescription and non-prescription pet medications, health products, and other animal supplies.

PetMed Express, Inc. (NASDAQ:PETS) was seen in the portfolios of 15 hedge funds in the fourth quarter, with a total stake value of $34.1 million.

Despite being on our list of oversold stocks, PetMed Express, Inc. (NASDAQ:PETS) may be a good healthcare stock to buy, just like Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Company (NYSE:BMY), and AbbVie Inc. (NYSE:ABBV).

Click to continue reading and see the 5 Oversold Healthcare Stocks To Buy Right Now.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months

• BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.

• One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Content: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

11 Oversold Healthcare Stocks To Buy Right Now

Published on March 13, 2024 at 8:17 am by Fatima Farooq in Hedge Funds, News

The Healthcare Sector: The New 2024 Idea?

Obesity and Weight Loss Drugs: A Newly Popular Area in Healthcare

Oversold Healthcare Stocks To Buy Right Now

11. 10x Genomics, Inc. (NASDAQ:TXG)

10. MaxCyte Inc. (LON:MXCT)

9. Seres Therapeutics, Inc. (NASDAQ:MCRB)

8. Integra Lifesciences Holdings Corporation (NASDAQ:IART)

7. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

6. PetMed Express, Inc. (NASDAQ:PETS)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

11 Oversold Healthcare Stocks To Buy Right Now

Published on March 13, 2024 at 8:17 am by Fatima Farooq in Hedge Funds, News

Share

The Healthcare Sector: The New 2024 Idea?

Obesity and Weight Loss Drugs: A Newly Popular Area in Healthcare

Oversold Healthcare Stocks To Buy Right Now

11. 10x Genomics, Inc. (NASDAQ:TXG)

10. MaxCyte Inc. (LON:MXCT)

9. Seres Therapeutics, Inc. (NASDAQ:MCRB)

8. Integra Lifesciences Holdings Corporation (NASDAQ:IART)

7. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

6. PetMed Express, Inc. (NASDAQ:PETS)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff